Ruby Miller is a scientist and policy-focused researcher committed to advancing early-stage biotechnologies for real-world impact. Miller integrates scientific innovation, regulatory strategy, and public benefit, and focuses on how emerging technologies transition from discovery to application.
Recently, Miller served as an innovation fellow at the University of Michigan’s Biointerfaces Institute (BI), advising researchers developing biotech and medtech innovations. As a fellow, she performed due diligence assessments of technologies, their markets, and relevant regulatory policies. She then led customer discovery initiatives to evaluate product–market fit and identify adoption barriers, while also supporting multiple Small Business Innovation Research (SBIR) submissions. Miller also coordinated communication strategies to promote the BI technology portfolio and advance external engagement, aligning university stakeholders and strengthening interdisciplinary collaborations.
Miller earned a Ph.D. in chemistry from the University of Michigan, where she developed next-generation genetic reporter systems to study G-protein coupled receptor (GPCR) signaling in opioid addiction pathways. Her doctoral research earned an National Institutes of Health Ruth L. Kirschstein F31 Predoctoral Fellowship, and she co-authored a peer-reviewed publication describing a high-throughput screening method for detecting GPCR activation.
Miller has applied systems-level thinking to regulatory projects, such as analyzing biosimilar and generic approval pathways while consulting for a task force on global access strategies. Her work is backed by formal training from the Ford School’s Science, Technology, and Public Policy certificate program. As President of the graduate student group Engaging Scientists in Policy and Advocacy (ESPA), Miller organized and led science policy programs. Additionally, she has honed her policy writing as both a Science Communication Fellow and an author for the MIT Science Policy Review.
Throughout her career, Miller has earned a reputation for interdisciplinary collaboration, strategic thinking, and leadership. Driven by a commitment to health equity, she is dedicated to strengthening regulatory science so that innovative, safe, and effective technologies reach those who need them most.